Physician profile
David Guillory
NPI 1558313742
$1,052.17
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $410 · 2023: $230 · 2024: $20.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $150.29 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $142.30 | 2022-2023 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $110.53 | 2023 | Rexulti |
| Corium, LLC | $109.23 | 2021 | |
| Lilly USA, LLC | $89.64 | 2021-2023 | Mounjaro |
| Abbvie INC. | $74.14 | 2021-2022 | |
| Genentech USA, INC. | $64.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.61 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $40.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.14 | 2022 | |
| Amarin Pharma, INC. | $35.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.56 | 2021 | |
| Boston Scientific Corporation | $21.17 | 2023 | Synergy |
| Abiomed | $20.27 | 2024 | Impella |
| Glaxosmithkline, LLC. | $19.94 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.89 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.92 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.68 | 2022 | |
| Novo Nordisk INC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Guillory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.